In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. More participants might be enrolled at the recognized monotherapy dosign routine. In Section B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "incorporate-on" therapy. In Section C, contributors https://abbv-744-brd4-inhibitor-m79135.blogadvize.com/39206131/the-2-minute-rule-for-abbv-744-in-the-treatment-of-drug-resistant-cancers